Cardiovascular Health

1. BioSignal Quick Verdict

• What determines cardiovascular health? Cardiovascular disease is overwhelmingly a disease of

atherosclerosis driven by modifiable factors — apoB-containing lipoproteins (LDL and kin), blood pressure, smoking, diabetes/metabolic health, diet, activity, and inflammation. In the landmark INTERHEART study, nine modifiable factors explained ~90% of the risk of a first heart attack [R1]. Heart disease is largely not an inevitable consequence of aging.

• How is risk measured? By a panel, not one number: blood pressure, a lipid profile

(LDL-C, and increasingly ApoB — the atherogenic-particle count) [R3], triglycerides/HDL, a once-in- a-lifetime Lp(a) [R5], plus risk scores and, when risk is uncertain, a coronary artery calcium (CAC) scan, which sharpens prediction beyond standard factors [R11]. Inflammation (hs-CRP) adds information [R9].

• What lowers risk (strongest evidence)? Lowering apoB/LDL (each 1 mmol/L reduction ≈ 22% fewer

major vascular events) [R7]; lowering blood pressure (each 10 mmHg systolic ≈ 20% fewer events) [R8]; not smoking; exercise and fitness (both aerobic and resistance) [R19, R20]; healthy dietary patterns (Mediterranean; replacing saturated with unsaturated fat) [R12, R13]; salt reduction / potassium-rich salt substitution [R17, R18]; and treating metabolic disease (GLP-1 therapy cuts events in obesity) [R23].

• What the evidence does NOT support (popular claims that fail). LDL doesn't matter — false; LDL/ApoB

are causal [R2]. High HDL protects everyone — false; raising HDL does not reduce events [R4]. Seed oils cause heart disease — false; replacing saturated fat with these oils lowers risk [R13, R14]. Eggs cause heart attacks — not supported for moderate intake [R16]. Red wine is heart-healthy — false; alcohol offers no cardiovascular protection [R21, R22]. Supplements can replace statins — false; none matches LDL-lowering event reduction [R7]. Cardio is the only exercise — false [R19, R20].

• Overall confidence: High that LDL/ApoB and blood pressure are causal and that lowering them reduces

events, that fitness and healthy diet lower risk, and that CVD is largely modifiable [R1, R2, R7, R8]; Moderate-High for ApoB superiority, Lp(a), CAC, inflammation, and salt substitution [R3, R5, R11, R9, R18]; Contradicted for the HDL, red-wine, and "LDL doesn't matter" myths [R4, R21].

• Evidence stability: High for the causal-lipid and blood-pressure cores and the modifiable-risk

thesis; Moderate for the fast-moving areas (Lp(a) therapeutics, inflammation targeting).

• One-sentence bottom line: *Cardiovascular disease is largely a preventable, measurable, and modifiable

condition — lower your apoB/LDL and blood pressure, don't smoke, stay fit with both aerobic and strength exercise, eat a healthy pattern, and treat metabolic disease — and most of the popular cardiovascular "hacks" and scares (HDL-boosting, seed-oil fear, egg panic, red-wine health halos, supplement substitutes) are distractions from those fundamentals.*

• Most common misconception: *That heart disease is an unavoidable part of getting older, or that any

single number (HDL, a glucose spike, a "clean" diet) settles your risk. Risk is a modifiable panel*, and the causal levers — apoB/LDL and blood pressure — are well established [R1, R2, R8].

2. Executive Summary

Cardiovascular disease is the world's leading cause of death — and it is largely modifiable. The dominant process is atherosclerosis: the decades-long accumulation of apoB-containing lipoprotein particles (LDL and its relatives) within artery walls, amplified by high blood pressure, smoking, diabetes, and inflammation, until a plaque ruptures and causes a heart attack or stroke. That this process is not inevitable is one of the most important facts in medicine: in the INTERHEART study of ~30,000 people across 52 countries, nine modifiable risk factors accounted for roughly 90% of the population risk of a first myocardial infarction [R1]. Cardiovascular health, then, is best understood as a modifiable, measurable state, not a fate.

How risk is measured has matured beyond a single cholesterol number. The causal driver is the apoB-containing lipoprotein burden: LDL-C is the familiar proxy, but ApoB — a direct count of atherogenic particles — is a more accurate marker, particularly when LDL-C and particle number diverge (as in high-triglyceride, metabolic states) [R3]. Lipoprotein(a), a genetically determined, largely fixed particle, is an independent causal risk factor that standard panels miss and that should be measured at least once [R5, R6]. Blood pressure is a second master variable. Beyond biomarkers, coronary artery calcium (CAC) imaging directly visualizes atherosclerosis and reclassifies risk beyond standard factors, helping decide who benefits from treatment [R11]; inflammation (hs-CRP) adds further information [R9].

The evidence for what lowers risk is among the strongest in all of medicine, and it is causal. Genetics, epidemiology, and randomized trials converge to establish that LDL/apoB causes atherosclerosis and that lowering it reduces events proportionally to the absolute reduction — each 1 mmol/L (~39 mg/dL) lower LDL-C yields roughly a 22% reduction in major vascular events per year of treatment [R2, R7]. Likewise, lowering blood pressure reduces events dose-dependently — about 20% fewer major cardiovascular events per 10 mmHg systolic reduction [R8], with intensive control benefiting high-risk patients [R10]. Inflammation is causally involved: targeting interleukin-1β with canakinumab reduced recurrent events independent of lipids in the CANTOS trial — a proof of concept (not a routine therapy) that atherosclerosis is an inflammatory as well as a lipid disease [R9]. On the lifestyle side, cardiorespiratory fitness strongly predicts outcomes [R19]; Mediterranean dietary patterns reduce events [R12]; replacing saturated fat with unsaturated fat (including vegetable/seed oils) lowers coronary heart disease in both cohorts and RCTs [R13, R14]; higher fiber intake is protective [R15]; sodium reduction and potassium-rich salt substitution lower blood pressure and cardiovascular events [R17, R18]; and treating metabolic disease helps — GLP-1 therapy reduced major cardiovascular events by ~20% in people with obesity but without diabetes [R23].

BioSignal is equally clear about the popular claims the evidence refutes, and it gives those refutations full visibility. "LDL doesn't matter" is wrong — LDL/apoB are causal [R2]. "High HDL protects everyone" is wrong — genetic and trial evidence show that raising HDL-C does not reduce events [R4]. "Seed oils cause heart disease" is backwards — replacing saturated fat with these polyunsaturated oils lowers coronary risk [R13, R14]. "Eggs cause heart attacks" is not supported for moderate consumption [R16]. "Red wine is heart-healthy" does not survive genetic evidence, which shows alcohol raises vascular risk with no protective threshold [R21, R22]. And "supplements can replace statins" fails: no supplement matches the apoB/LDL-lowering event reduction that underlies guideline therapy for high-risk patients [R7] — lifestyle is foundational, but it complements rather than replaces indicated treatment.

BioSignal's overall verdict: cardiovascular health is a high-confidence, high-return, and largely modifiable domain. The causal levers — apoB/LDL and blood pressure — are established beyond reasonable doubt, the lifestyle fundamentals (fitness, dietary pattern, not smoking, metabolic health) are strongly supported, and the field's greatest enemies are misinformation and single-number reductionism, which this hub is written to correct.

3. Mechanisms — How Cardiovascular Disease Develops

Atherosclerosis is the core process. apoB-containing lipoproteins — chiefly LDL, but also VLDL remnants and Lp(a) — cross the arterial lining and become trapped and modified in the vessel wall. Because each particle carries one apoB molecule, the number of atherogenic particles (indexed by apoB) governs how many can enter and lodge — which is why apoB can be a more faithful risk marker than the cholesterol mass those particles carry (LDL-C) [R3]. Trapped particles trigger an immune-inflammatory response: monocytes enter, become foam cells, and form a fatty plaque. This is why inflammation is not incidental but causal — pharmacologically dampening it reduced events in CANTOS [R9].

Cumulative exposure, not a threshold, drives risk. The relationship between LDL/apoB and disease is log-linear and cumulative — the arterial damage reflects both the level and the duration of exposure, which is why lifelong lower LDL (as in genetic low-LDL variants) confers large protection and why "my LDL is only a bit high" understates lifetime risk [R2].

Blood pressure and shear stress. Hypertension injures the endothelium and accelerates plaque formation and rupture, and stresses the heart and kidneys; lowering it interrupts this mechanically and biologically, with benefit proportional to the reduction [R8]. Sodium raises blood pressure by expanding volume; potassium counteracts it — the mechanistic basis for salt reduction and potassium-enriched salt substitutes [R17, R18].

The metabolic amplifiers. Insulin resistance and diabetes worsen the lipid profile (more small, dense, triglyceride-rich apoB particles), raise blood pressure, and promote inflammation — linking metabolic health tightly to cardiovascular risk and explaining why treating metabolic disease (including with GLP-1 therapy) lowers cardiovascular events [R23]. Smoking injures the endothelium and is pro-thrombotic and pro-inflammatory.

Why HDL is different. HDL-C marks risk (low HDL tracks with metabolic dysfunction), but Mendelian randomization and failed HDL-raising trials show it is not causally protective — HDL function, not the cholesterol number, is what mechanistic interest now centers on [R4].

The plaque, not just the number. Coronary calcium reflects the healed footprint of atherosclerosis; a CAC score is therefore a direct readout of disease burden that integrates a lifetime of exposures — which is why it predicts events beyond the standard risk factors [R11].

4. Body Systems & Domains Affected

• Arterial wall / vasculature — the site of atherosclerosis; apoB particles, blood pressure, and

inflammation drive plaque [R2, R8, R9]. (Mechanistic + causal.)

• Lipid & lipoprotein metabolism — LDL-C, ApoB, triglycerides, HDL-C, Lp(a): the biomarker layer [R3, R5].

(Biomarker; ApoB/LDL causal, HDL not.)

• Cardiac — coronary artery disease → myocardial infarction, heart failure; CAC images coronary burden

[R11]. (Imaging/outcome.)

• Cerebrovascular — stroke shares the same drivers; BP and salt substitution especially affect stroke

[R8, R18]. (RCT + observational.)

• Metabolic — diabetes, insulin resistance, and obesity amplify risk; GLP-1 therapy lowers events [R23].

(RCT + observational — see the Metabolic Health hub.)

• Immune / inflammatory — atherosclerosis is an inflammatory disease; hs-CRP marks residual risk [R9].

(RCT proof-of-concept.)

• Cardiorespiratory fitness / musculoskeletal — fitness predicts outcomes; exercise (aerobic + resistance)

lowers risk [R19, R20]. (Observational + guideline.)

• Whole-organism (prevention & longevity) — CVD is largely modifiable; prevention extends healthy life

[R1]. (Observational + trials.)

5. Major Claims — Evidence Evaluation

Each claim carries a stable id (claim-N), a verdict and confidence (Evidence Rating Framework §6 verdicts, §4 confidence, §5 decision tree), the evidence with its type distinguished (biomarker / mechanism / intervention / prevention vs. treatment; genetic / observational / randomized / guideline), conflicting evidence, limitations, and an explicit "what would change our mind." Claims marked (primary outcome) are load-bearing; (consumer claim) addresses a named popular belief. Consistent with scope, medications are treated at a high level; detailed appraisals belong to future Signal Records.

claim-1 — "Cardiovascular disease is largely modifiable, not an inevitable consequence of aging." (consumer claim; primary outcome)

• Verdict: Supported (myth "inevitable with age" Contradicted). · Confidence: High.
• Evidence. INTERHEART (~30,000 people, 52 countries): nine modifiable risk factors (smoking,

apoB/apoA1 lipids, hypertension, diabetes, abdominal obesity, diet, activity, alcohol, psychosocial) account for ~90% of the population-attributable risk of a first MI [R1]. (Large case-control; observational.)

• Evidence quality. Tier 3 (very large international case-control), coherent with trial evidence for each

factor.

• Conflicting evidence / limitations. Age and genetics are non-modifiable contributors; "90% of risk is

modifiable" is population-attributable, not a personal guarantee.

• What would change our mind. Evidence that most CV risk is non-modifiable (contrary to the trial base for

each risk factor).

claim-2 — "LDL/apoB-containing lipoproteins are causal in atherosclerosis, and lowering them reduces events." (consumer claim; primary outcome)

• Verdict: Supported (myth "LDL doesn't matter" Contradicted). · Confidence: High.
• Evidence. The EAS consensus integrates **genetic (Mendelian randomization), epidemiologic, and

randomized-trial evidence to establish LDL causes ASCVD, with a cumulative, dose-dependent effect [R2]; the CTT meta-analysis of ~170,000 trial participants shows each 1 mmol/L LDL-C reduction lowers major vascular events ~22% per year, proportional to the absolute reduction [R7]; on intravascular imaging, statin-induced reductions in LDL-C and CRP* slow coronary plaque progression [R24]. (Genetic + observational + RCT + imaging — full triangulation.)*

• Evidence quality. Tier 1 (convergent genetic + RCT meta-analysis) — among the strongest causal cases in

medicine.

• Conflicting evidence / limitations. Absolute benefit depends on baseline risk; the marker debate

(LDL-C vs apoB, claim-3) does not weaken the causal conclusion.

• What would change our mind. Nothing credible; overturning would require contradicting convergent genetic

and randomized evidence.

claim-3 — "ApoB is a more accurate risk marker than LDL-C." (biomarker; primary outcome)

• Verdict: Supported. · Confidence: Moderate-High.
• Evidence. ApoB counts atherogenic particles (one apoB per LDL/VLDL/Lp(a) particle) and better

captures risk when LDL-C and particle number diverge (high triglycerides, metabolic syndrome) [R3]. (Narrative/mechanistic review + epidemiology.)

• Evidence quality. Tier 2–3.
• Conflicting evidence / limitations. In most people LDL-C and apoB agree; apoB's added value is greatest

in discordance. Measurement/availability and guideline adoption vary.

• What would change our mind. Evidence that LDL-C predicts and guides treatment as well as apoB even in

discordant, high-triglyceride patients.

claim-4 — "Raising HDL cholesterol protects the heart / high HDL protects everyone." (consumer claim; primary outcome)

• Verdict: Contradicted. · Confidence: Moderate-High.
• Evidence. Mendelian randomization found genetically raised HDL-C not associated with lower MI risk,

while genetically lower LDL was protective [R4]; HDL-raising drug trials (CETP inhibitors, niacin) failed to reduce events. HDL-C marks risk but is not causally protective. (Genetic + RCT.)

• Evidence quality. Tier 1–2 (Mendelian randomization + failed RCTs).
• Conflicting evidence / limitations. Low HDL still flags metabolic risk; very high HDL may even track

higher mortality — so "higher is always better" is doubly wrong.

• What would change our mind. An HDL-targeted therapy that reduces hard cardiovascular events (none has).

claim-5 — "Lipoprotein(a) is a genetically determined, causal, independent cardiovascular risk factor." (biomarker; primary outcome)

• Verdict: Supported. · Confidence: Moderate-High.
• Evidence. Genetically elevated Lp(a) causally increases MI risk (HR ~1.22 per doubling on

instrumental analysis) [R5], and the EAS consensus affirms a continuous causal association with CVD and aortic stenosis, independent of LDL-C [R6]. (Genetic + epidemiologic.)

• Evidence quality. Tier 1–3 (Mendelian randomization + consensus).
• Conflicting evidence / limitations. No approved Lp(a)-lowering therapy yet proven to reduce events

(trials ongoing) — so Lp(a) currently guides risk stratification and intensification of other levers, not a specific drug.

• What would change our mind. For the causal claim, little; for management, a positive Lp(a)-lowering

outcome trial would add a treatment.

claim-6 — "Lowering blood pressure reduces cardiovascular events." (intervention; primary outcome)

• Verdict: Supported. · Confidence: High.
• Evidence. Each 10 mmHg systolic reduction lowers major CV events ~20%, coronary disease ~17%,

stroke ~27%, and mortality ~13% across trials [R8]; intensive control (<120) reduced events and mortality in high-risk patients (SPRINT) [R10]. (RCT meta-analysis + landmark RCT.)

• Evidence quality. Tier 1 (mega-meta-analysis + RCT).
• Conflicting evidence / limitations. Optimal targets are individualized (frailty, orthostasis, kidney

function); intensive control raises some harms (see Safety). Specific drug choice is out of scope (future Signal Records).

• What would change our mind. Trials showing no event reduction from BP lowering (contrary to a vast base).

claim-7 — "Inflammation is causally involved in atherosclerosis." (mechanism/biomarker; primary outcome)

• Verdict: Supported. · Confidence: Moderate-High.
• Evidence. In CANTOS, the anti-inflammatory canakinumab (IL-1β) reduced recurrent cardiovascular

events independent of lipid lowering — a proof of concept that inflammation is causal [R9]; hs-CRP marks residual risk. (RCT.)

• Evidence quality. Tier 2 (landmark RCT).
• Conflicting evidence / limitations. Canakinumab is not routine therapy (cost, infection risk, no

mortality benefit); the practical translation is emerging (e.g., colchicine). This establishes mechanism, not a standard treatment.

• What would change our mind. Failure of other anti-inflammatory agents to reduce events (mixed to date).

claim-8 — "Coronary artery calcium (CAC) scoring improves cardiovascular risk stratification." (biomarker/imaging; primary outcome)

• Verdict: Supported. · Confidence: Moderate-High.
• Evidence. In MESA, CAC independently predicted coronary events across ethnic groups and improved

prediction beyond standard risk factors [R11]; a CAC of zero identifies low short-term risk, while high CAC reclassifies upward. (Prospective cohort.)

• Evidence quality. Tier 3 (large prospective cohort) — for prediction/reclassification.
• Conflicting evidence / limitations. CAC is a decision aid for intermediate-risk patients, not a

universal screen; it involves radiation and cost and does not itself reduce events.

• What would change our mind. Evidence that CAC adds no value over standard risk assessment.

claim-9 — "Cardiorespiratory fitness predicts cardiovascular outcomes, and improving it lowers risk." (primary outcome)

• Verdict: Supported. · Confidence: High (predictor) / Moderate-High (improving → outcomes).
• Evidence. Each 1-MET higher fitness is associated with ~15% lower cardiovascular event risk

[R19]; guidelines recommend activity for CV prevention [R20]. (Observational + guideline; RCT for fitness gains.)

• Evidence quality. Tier 1–3.
• Conflicting evidence / limitations. Fitness is partly genetic; the fitness–outcome link is observational,

though the direction is secure.

• What would change our mind. Evidence that improving fitness does not lower events.
• Cross-link: the Exercise (CM-008) Health Domain.

claim-10 — "Cardio is the only exercise that matters for the heart." (consumer claim)

• Verdict: Contradicted. · Confidence: Moderate-High.
• Evidence. Both aerobic and resistance training benefit cardiovascular health; guidelines recommend

aerobic plus muscle-strengthening [R20], and combined training is associated with the lowest risk [R19]. (Guideline + observational.)

• Evidence quality. Tier 1 guideline + Tier 3 cohorts.
• Conflicting evidence / limitations. Aerobic exercise most directly raises cardiorespiratory fitness;

resistance adds metabolic and functional benefit — they are complementary, not competitive.

• What would change our mind. Evidence that resistance training confers no cardiovascular benefit.
• Cross-link: the Exercise and Resistance Training monographs.

claim-11 — "Healthy dietary patterns reduce cardiovascular risk — and 'seed oils cause heart disease' is false." (consumer claim; primary outcome)

• Verdict: Supported (pattern); myth "seed oils cause heart disease" Contradicted. · **Confidence:

Moderate-High.**

• Evidence. The Mediterranean diet reduced major CV events (~30%) in the PREDIMED RCT [R12]; **replacing

saturated fat with polyunsaturated fat (including vegetable/seed oils) is associated with lower CHD (5% energy swap → ~25% lower risk) in cohorts [R13] and reduced CHD events ~19%* in an RCT meta-analysis [R14]. (RCT + observational.)*

• Evidence quality. Tier 1–3.
• Conflicting evidence / limitations. "Dietary pattern" evidence is partly observational; PREDIMED had a

corrected reanalysis. The seed-oil fear is contradicted, but whole dietary pattern matters more than any single oil.

• What would change our mind. RCTs showing seed-oil/PUFA replacement raises CHD (contrary to trial

evidence).

claim-12 — "Higher dietary fiber lowers cardiovascular risk." (intervention; primary outcome)

• Verdict: Supported. · Confidence: Moderate-High.
• Evidence. Higher fiber intake is associated with lower cardiovascular disease and mortality in a

dose-response, and soluble fiber lowers LDL-C [R15]. (Observational + RCT for lipids.)

• Evidence quality. Tier 2–3.
• Conflicting evidence / limitations. Disease-outcome data are observational; lipid effects are RCT-solid.
• What would change our mind. Cohorts/trials showing no cardiovascular benefit of fiber.
• Cross-link: the Fiber monograph (CM-005).

claim-13 — "Eggs / dietary cholesterol cause heart attacks." (consumer claim)

• Verdict: Not Established (the causal-harm claim is not established; no association at moderate intake). ·

Confidence: Limited.

• Evidence. In three large US cohorts plus meta-analysis, moderate egg consumption (up to ~1/day) was

not associated with cardiovascular disease overall (pooled RR ~0.98) [R16] — evidence against the harm claim, but purely observational, which caps confidence at Limited. (Observational.)

• Evidence quality. Tier 3 (large cohorts + meta-analysis).
• Conflicting evidence / limitations. Individual responses to dietary cholesterol vary; associations may

differ in diabetes and at very high intakes; overall dietary pattern matters more than eggs alone.

• What would change our mind. Consistent evidence that moderate egg intake raises CV events.

claim-14 — "Reducing sodium and using potassium-rich salt substitution lower blood pressure and events." (intervention; primary outcome)

• Verdict: Supported. · Confidence: Moderate-High.
• Evidence. Lower dietary sodium reduces blood pressure (DASH-Sodium RCT) [R17], and a **potassium-

enriched salt substitute reduced stroke, major CV events, and death* in a large RCT (SSaSS) [R18]. (RCT.)*

• Evidence quality. Tier 1–2 (RCTs).
• Conflicting evidence / limitations. The sodium–hard-outcome relationship at the population level is

debated (possible J-curve at very low intake); potassium substitutes require caution in kidney disease (hyperkalemia).

• What would change our mind. Trials showing salt substitution does not reduce events, or clear net harm

from moderate sodium reduction.

claim-15 — "Red wine / moderate alcohol is heart-healthy." (consumer claim; primary outcome)

• Verdict: Contradicted. · Confidence: Moderate-High.
• Evidence. Genetic (Mendelian randomization) evidence in 500,000 adults shows alcohol raises stroke

risk roughly linearly with no protective threshold [R21]; the Global Burden of Disease analysis concludes no level of alcohol improves health overall [R22]. The old "J-curve" reflected confounding (ex-drinkers, healthy-drinker bias). (Genetic + global epidemiology.)

• Evidence quality. Tier 1–3 (Mendelian randomization + GBD).
• Conflicting evidence / limitations. Some observational studies still show a J-curve for coronary

endpoints, but genetic evidence undercuts causality; any small coronary signal is outweighed by stroke, cancer, and other harms.

• What would change our mind. Mendelian-randomization or RCT evidence of a genuine net cardiovascular

benefit of moderate alcohol (none exists).

claim-16 — "Metabolic disease and obesity drive cardiovascular risk, and treating them (incl. GLP-1) lowers events." (intervention; primary outcome)

• Verdict: Supported. · Confidence: High.
• Evidence. Diabetes and metabolic dysfunction are major CV drivers; in the SELECT RCT, **semaglutide

reduced major cardiovascular events ~20% in people with obesity without diabetes* [R23]. (RCT.)*

• Evidence quality. Tier 2 (large RCT).
• Conflicting evidence / limitations. GLP-1 therapy is a medical decision (cost, side effects, regain

on stopping); a full appraisal is out of scope (Metabolic Health hub + future Signal Record).

• What would change our mind. Long-term data materially changing the benefit–risk balance.
• Cross-link: the Metabolic Health monograph (CM-009).

claim-17 — "Supplements can replace statins (or lifestyle alone suffices) for high cardiovascular risk." (consumer claim; primary outcome)

• Verdict: Contradicted. · Confidence: Moderate-High.
• Evidence. The event reduction from apoB/LDL lowering is proportional to the absolute LDL reduction

achieved [R7]; no supplement produces the magnitude and durability of LDL lowering that guideline therapy does, and head-to-head studies show supplements do not match statins for LDL reduction. Lifestyle is foundational but does not, by itself, replace indicated therapy in high-risk patients. (RCT meta-analysis + comparative trials.)

• Evidence quality. Tier 1–2.
• Conflicting evidence / limitations. Lifestyle can substantially lower risk and, in lower-risk people, may

suffice; this claim concerns high-risk patients for whom therapy is indicated. Specific drug appraisal is out of scope (future Signal Records).

• What would change our mind. A supplement shown in RCTs to match statin-level LDL lowering and event

reduction.

6. Question Resolution (Selected)

• What is the single most important number? There isn't one — but the apoB/LDL burden and **blood

pressure are the two causal levers with the strongest evidence [R2, R7, R8]. Prefer ApoB** where available [R3].

• Should I get my Lp(a) checked? Yes, at least once — it is genetically set, causal, and missed by

standard panels; it changes how aggressively to manage everything else [R5, R6].

• When is a coronary calcium scan useful? When risk is intermediate or uncertain and it would change

treatment — CAC reclassifies risk beyond standard factors [R11].

• Does LDL really matter? Yes — it is causal. The debate is about the best marker (apoB vs LDL-C),

not about whether lowering it helps [R2, R7].

• Is high HDL good? HDL-C marks risk but raising it doesn't protect — don't chase it [R4].
• Are seed oils and eggs bad for the heart? No. Replacing saturated fat with unsaturated (incl. seed)

oils lowers CHD [R13, R14]; moderate eggs are not associated with CVD [R16].

• Is red wine heart-healthy? No — alcohol offers no cardiovascular protection [R21, R22].
• Can supplements replace statins? No — none matches guideline LDL-lowering for high-risk patients;

lifestyle and medication work together [R7].

• Is heart disease inevitable as I age? No — it is largely modifiable [R1].

7. Confidence Justification

Ratings follow the Evidence Rating Framework (§4 levels, §7 calibration), each capped where capped.

• High is reserved for the domain's causal core — LDL/apoB causality and LDL-lowering benefit (genetic

+ RCT triangulation) [R2, R7], blood-pressure lowering [R8, R10], fitness as a predictor [R19], and GLP-1 event reduction [R23], and the modifiable-risk thesis [R1].

• Moderate-High, not High, for ApoB superiority [R3], Lp(a) causality [R5, R6], CAC

reclassification [R11], inflammation causality [R9], dietary pattern / seed-oil and fiber effects [R11-diet, R13–R15], and salt substitution [R18] — capped by observational components, single-trial reliance, or (for Lp(a)/inflammation) the absence of a proven routine therapy.

• Limited for the eggs null [R16] (observational, individual variation) — a Not Established verdict

on the harm claim, kept humble because the evidence is observational.

• Contradicted designations — HDL raising protects [R4], red wine is heart-healthy [R21, R22],

LDL doesn't matter [R2], cardio is the only exercise [R20], and supplements replace statins [R7] — are stated with Moderate-High confidence in the negative, grounded in genetic evidence, failed trials, or the proportional-benefit data.

No rating is assigned without the documentation above (Framework §12). Genetic, observational, randomized, and guideline evidence are distinguished throughout, and negative results (HDL-raising, alcohol) receive the same visibility as the positive causal findings.

8. Remaining Unknowns

Unknowns receive equal visibility with the positive findings:

• Whether Lp(a)-lowering therapies reduce events (outcome trials ongoing) [R5, R6].
• How best to translate inflammation targeting into routine practice (which agents, whom) [R9].
• The true shape of the sodium–hard-outcome curve at very low intakes [R17].
• Optimal blood-pressure and LDL targets across age, frailty, and risk [R8, R10].
• The independent contribution of stress and sleep to cardiovascular events (see those Health Domains).
• Long-term GLP-1 cardiovascular outcomes and discontinuation effects [R23].
• The best risk-estimation tools across diverse populations (calibration varies).

9. Clinical Context (Populations)

• General adults. Know your blood pressure, apoB/LDL, and Lp(a) (once); maintain fitness, a

healthy dietary pattern, no smoking, and metabolic health [R1, R3, R5].

• Intermediate/uncertain risk. Consider CAC to guide whether to intensify prevention [R11].
• High risk / established disease. apoB/LDL and blood-pressure lowering are foundational; lifestyle

complements, does not replace, indicated therapy [R7, R8]. (Drug specifics: future Signal Records.)

• People with high Lp(a) or family history. Manage all other levers more aggressively; cascade screening

of relatives [R5, R6].

• Diabetes / metabolic disease / obesity. Cardiovascular risk is elevated; treat metabolic disease,

consider GLP-1 where indicated [R23]. See the Metabolic Health hub.

• Older adults. Benefits of BP and lipid management persist, but individualize targets for frailty and

polypharmacy (see Healthy Aging).

• Kidney disease. Caution with potassium-based salt substitutes (hyperkalemia risk) [R18].

10. Safety

Prevention is overwhelmingly beneficial, but intensity must be individualized, and safety is neither inflated nor minimized.

• Intensive blood-pressure lowering reduces events but can cause **hypotension, syncope, falls, acute

kidney injury, and electrolyte disturbance**, especially in older or frail patients — targets are individualized [R8, R10].

• Potassium-enriched salt substitutes lower events but risk hyperkalemia in chronic kidney disease

or with potassium-sparing drugs — not for everyone [R18].

• Lipid-lowering and other medications carry their own profiles and are prescribed and monitored by a

clinician; this hub does not provide medication guidance (see future Signal Records).

• Exercise is safe and protective; those with known or suspected cardiovascular disease should seek

evaluation before vigorous exertion (see Exercise) [R20].

• "Natural" substitution risk. Replacing proven therapy with supplements in high-risk patients is a

real harm — it forgoes established event reduction [R7].

• When to seek medical evaluation. Chest pain, breathlessness, or exertional symptoms; a strong family

history or high Lp(a); and before major changes to prevention or any medication decision. This hub is educational and an adjunct to individualized medical care, never a replacement for it.

11. Practical Guidance (Educational — Not Individual Advice)

12. Special Topics (Concise)

• ApoB vs LDL-C — the marker, not the mechanism. The debate is which number best counts atherogenic

particles; both point the same way — lower is better, and lowering is causal [R2, R3].

• Lp(a) — the missing inherited risk. Cheap to measure once; currently guides how hard to pull the other

levers, with targeted therapies in trials [R5, R6].

• Inflammation — real but not yet routine. CANTOS proved the concept; translating it (e.g., colchicine)

into practice is evolving [R9].

• The "J-curve" myths. For alcohol, genetic evidence dissolves the apparent J-curve [R21]; for

sodium, the low-intake tail is genuinely uncertain [R17] — BioSignal states each honestly rather than picking a side.

• Biomarkers as navigation. LDL-C, ApoB, HDL-C, triglycerides, Lp(a), CAC, and hs-CRP are intended as

first-class Biomarker objects in the BioSignal graph, each with its own future Signal Record.

13. Cardiovascular Risk & Interventions Map (Educational)

14. Common Myths

• "LDL doesn't matter." Contradicted. LDL/apoB are causal; lowering them reduces events, proportional

to the absolute reduction [R2, R7].

• "High HDL protects everyone." Contradicted. Raising HDL-C does not lower events; HDL marks but does

not cause protection [R4].

• "Seed oils cause heart disease." Contradicted. Replacing saturated fat with these unsaturated oils

lowers CHD [R13, R14].

• "Eggs cause heart attacks." Not Established. Moderate egg intake is not associated with CVD in most

people [R16].

• "Red wine is heart-healthy." Contradicted. Alcohol offers no cardiovascular protection; no safe

level [R21, R22].

• "Supplements can replace statins." Contradicted. No supplement matches guideline apoB/LDL-lowering

event reduction in high-risk patients [R7].

• "Cardio is the only exercise that matters." Contradicted. Aerobic and resistance training both

benefit the heart [R19, R20].

• "Heart disease is inevitable with age." Contradicted. ~90% of first-MI risk is explained by

modifiable factors [R1].

15. Related Signals

Cardiovascular Health is a primary Health Domain hub of BioSignal Foundations, linking downward to the intervention Health Domains and the cardiovascular Signal Records, which are never merged into it.

• Related Health Domains (downward): Metabolic Health (CM-009, shared cardiometabolic risk),

Exercise (CM-008), Walking (CM-004), Resistance Training (CM-002), Fiber (CM-005), Sleep (CM-003), and Healthy Aging (CM-007).

• Related Signal Records & Biomarkers: Omega-3, Magnesium, CoQ10, Vitamin D; and the

Biomarker objects ApoB · LDL-C · HDL-C · Triglycerides · Lp(a) · CAC · hs-CRP · Blood Pressure. (Upward links: each record/biomarker → Cardiovascular Health.)

• Future Signal Records — statins, blood-pressure medications, aspirin, fish oil, sodium, potassium, CoQ10,

ApoB, Lp(a) — will provide the detailed appraisals this hub deliberately defers, and will link up here.

18. Future Research Priorities

• Lp(a)-lowering outcome trials [R5, R6].
• Practical anti-inflammatory cardiovascular therapy (agents, patient selection) [R9].
• The sodium low-intake outcome curve and personalized targets [R17].
• Optimal apoB/LDL and BP targets by age, risk, and frailty [R7, R8].
• Better risk estimation and imaging (CAC, plaque) integration across diverse populations [R11].
• Long-term GLP-1 cardiovascular outcomes [R23].

20. Complete Verified Reference List

Each entry was verified to source during authoring (PubMed, NCBI E-utilities, Crossref, and journal/publisher pages). PMIDs and DOIs are included where confirmed. This is a curated landmark tier, not an exhaustive bibliography.

• [R1] Yusuf S, Hawken S, Ôunpuu S, et al; INTERHEART Study Investigators. *Effect of potentially modifiable

risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-952. doi:10.1016/S0140-6736(04)17018-9. PMID: 15364185. (Nine modifiable factors ≈ 90% of first-MI population risk.)*

• [R2] Ference BA, Ginsberg HN, Graham I, et al. *Low-density lipoproteins cause atherosclerotic

cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144. PMID: 28444290. (LDL causes ASCVD; cumulative, dose-dependent.)*

• [R3] Sniderman AD, Thanassoulis G, Glavinovic T, et al. *Apolipoprotein B particles and cardiovascular

disease: a narrative review.* JAMA Cardiol. 2019;4(12):1287-1295. doi:10.1001/jamacardio.2019.3780. PMID:

1. (ApoB [particle number] a more accurate risk marker than LDL-C/non-HDL-C.)
2. [R4] Voight BF, Peloso GM, Orho-Melander M, et al. *Plasma HDL cholesterol and risk of myocardial

infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572-580. doi:10.1016/S0140-6736(12)60312-2. PMID: 22607825. (Genetically raised HDL-C did NOT lower MI risk — HDL not causally protective.)*

• [R5] Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. *Genetically elevated lipoprotein(a)

and increased risk of myocardial infarction.* JAMA. 2009;301(22):2331-2339. doi:10.1001/jama.2009.801. PMID:

1. (Causal: HR ~1.22 per doubling of Lp(a) on instrumental analysis.)
2. [R6] Kronenberg F, Mora S, Stroes ESG, et al. *Lipoprotein(a) in atherosclerotic cardiovascular disease

and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946. doi:10.1093/eurheartj/ehac361. PMID: 36036785. (Continuous causal association; measure at least once.)*

• [R7] Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, et al.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. doi:10.1016/S0140-6736(10)61350-5. PMID: 21067804. (Each 1 mmol/L LDL-C reduction ≈ 22% fewer major vascular events/year.)

• [R8] Ettehad D, Emdin CA, Kiran A, et al. *Blood pressure lowering for prevention of cardiovascular

disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957-967. doi:10.1016/S0140-6736(15)01225-8. PMID: 26724178. (Each 10 mmHg systolic reduction ≈ 20% fewer major CV events; stroke ~27%.)*

• [R9] Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. *Antiinflammatory therapy with

canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914. PMID: 28845751. (IL-1β inhibition reduced recurrent events independent of lipids — inflammation causal; proof of concept, not routine therapy.)*

• [R10] SPRINT Research Group; Wright JT Jr, Williamson JD, et al. *A randomized trial of intensive versus

standard blood-pressure control.* N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939. PMID:

1. (Intensive control reduced CV events and mortality in high-risk patients.)
2. [R11] Detrano R, Guerci AD, Carr JJ, et al. *Coronary calcium as a predictor of coronary events in four

racial or ethnic groups. N Engl J Med. 2008;358(13):1336-1345. doi:10.1056/NEJMoa072100. PMID: 18367736. (CAC independently predicts events; improves risk stratification beyond standard factors — MESA.)*

• [R12] Estruch R, Ros E, Salas-Salvadó J, et al. *Primary prevention of cardiovascular disease with a

Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378(25):e34. doi:10.1056/NEJMoa1800389. PMID: 29897866. (PREDIMED RCT: ~30% fewer major CV events.)*

• [R13] Li Y, Hruby A, Bernstein AM, et al. *Saturated fats compared with unsaturated fats and sources of

carbohydrates in relation to risk of coronary heart disease: a prospective cohort study. J Am Coll Cardiol. 2015;66(14):1538-1548. doi:10.1016/j.jacc.2015.07.055. PMID: 26429077. (Replacing SFA with PUFA [incl. seed oils]: 5% energy swap → ~25% lower CHD.)*

• [R14] Mozaffarian D, Micha R, Wallace S. *Effects on coronary heart disease of increasing polyunsaturated

fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2010;7(3):e1000252. doi:10.1371/journal.pmed.1000252. PMID: 20351774. (RCT meta: replacing SFA with PUFA reduced CHD events ~19%.)*

• [R15] Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. *Carbohydrate quality and human

health: a series of systematic reviews and meta-analyses. Lancet. 2019;393(10170):434-445. doi:10.1016/S0140-6736(18)31809-9. PMID: 30638909. (Higher fiber: lower CVD and mortality; dose-response.)*

• [R16] Drouin-Chartier JP, Chen S, Li Y, et al. *Egg consumption and risk of cardiovascular disease: three

large prospective US cohort studies, systematic review, and updated meta-analysis. BMJ. 2020;368:m513. doi:10.1136/bmj.m513. PMID: 32132002. (Moderate egg intake [≤~1/day] not associated with CVD; pooled RR ~0.98.)*

• [R17] Sacks FM, Svetkey LP, Vollmer WM, et al; DASH-Sodium Collaborative Research Group. *Effects on blood

pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344(1):3-10. doi:10.1056/NEJM200101043440101. PMID: 11136953. (Lower sodium and DASH each reduce BP; combined largest.)*

• [R18] Neal B, Wu Y, Feng X, et al. Effect of salt substitution on cardiovascular events and death. N

Engl J Med. 2021;385(12):1067-1077. doi:10.1056/NEJMoa2105675. PMID: 34459569. (SSaSS RCT: potassium-enriched salt substitute reduced stroke, major CV events, and death. Note: a wrong PMID [34459570] circulates — this is the correct one.)

• [R19] Kodama S, Saito K, Tanaka S, et al. *Cardiorespiratory fitness as a quantitative predictor of

all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA. 2009;301(19):2024-2035. doi:10.1001/jama.2009.681. PMID: 19454641. (Each 1-MET higher fitness ≈ 15% lower CHD/CVD.)*

• [R20] Bull FC, Al-Ansari SS, Biddle S, et al. *World Health Organization 2020 guidelines on physical

activity and sedentary behaviour. Br J Sports Med. 2020;54(24):1451-1462. doi:10.1136/bjsports-2020-102955. PMID: 33239350. (Aerobic + muscle-strengthening for cardiovascular prevention.)*

• [R21] Millwood IY, Walters RG, Mei XW, et al. *Conventional and genetic evidence on alcohol and vascular

disease aetiology: a prospective study of 500 000 men and women in China. Lancet. 2019;393(10183):1831-1842. doi:10.1016/S0140-6736(18)31772-0. PMID: 30955975. (Genetic evidence: alcohol raises stroke risk linearly, no protection.)*

• [R22] GBD 2016 Alcohol Collaborators. *Alcohol use and burden for 195 countries and territories,

1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.* Lancet. 2018;392(10152):1015-

1. doi:10.1016/S0140-6736(18)31310-2. PMID: 30146330. (No level of alcohol improves overall health.)
2. [R23] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. *Semaglutide and

cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563. PMID: 37952131. (~20% reduction in major adverse cardiovascular events.)*

• [R24] Nissen SE, Tuzcu EM, Schoenhagen P, et al; REVERSAL Investigators. *Statin therapy, LDL

cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352(1):29-38. doi:10.1056/NEJMoa042000. PMID: 15635110. (Statin-induced LDL-C and CRP reductions slow coronary plaque progression on IVUS.)*

Clickable identifiers: R1 INTERHEART (modifiable risk)17018-9) · R2 LDL causes ASCVD (EAS) · R3 ApoB narrative review · R4 HDL Mendelian randomisation60312-2) · R5 genetically elevated Lp(a) · R6 Lp(a) EAS consensus 2022 · R7 CTT LDL-lowering meta-analysis61350-5) · R8 BP lowering meta-analysis01225-8) · R9 CANTOS (inflammation) · R10 SPRINT (intensive BP) · R11 MESA coronary calcium · R12 PREDIMED (Mediterranean diet) · R13 saturated vs unsaturated fat & CHD · R14 PUFA-for-SFA RCT meta-analysis · R15 carbohydrate quality & fiber31809-9) · R16 eggs & cardiovascular disease · R17 DASH-Sodium · R18 salt substitution (SSaSS) · R19 cardiorespiratory fitness & CVD · R20 WHO 2020 physical activity · R21 alcohol & vascular disease (genetic)31772-0) · R22 GBD 2016 alcohol31310-2) · R23 semaglutide SELECT (CV) · R24 REVERSAL (statin, LDL, CRP, plaque)

21. Suggested Version Number

Version 1.0 (review-hardened) upon sign-off. This is the initial draft entering the Editorial Workflow, authored and self-audited through Phases 1–4; the provisional "1.0" stamp becomes "1.0 (review-hardened)" once senior scientific + medical sign-off is recorded.

• A minor update (1.1) would attach newer risk-estimation or imaging evidence and any additional Signal

Record cross-links — none of which changes a verdict.

• A major update (2.0) would follow any change to a verdict or a headline confidence rating — for

example, a positive Lp(a)-lowering outcome trial (adding a treatment to claim-5), practice-changing anti-inflammatory therapy (claim-7), or evidence materially changing the sodium or alcohol conclusions.

Never rewrite history: prior versions are preserved, changes documented, and any change in confidence explained.